[Ciprofloxacin, clarithromycin, rifampin: in vitro bactericidal activity of double and triple drug combinations against strains of atypical mycobacteria].
Bactericidal activity of ciprofloxacin (CIP), clarithromycin (CLA), rifampin (RIF) alone and in combinations was studied against five atypical mycobacteria (4 isolates from patients with Acquired Immunodeficiency Syndrome and 1 collection strain) by time killing curves method. Drugs were used at their attainable serum levels: CIP (1 microgram/ml), CLA (2 micrograms/ml), RIF (16 micrograms/ml). The decrease in CFU in comparison to inoculum (10(6)-10(7) CFU/ml) was evaluated by viable counts after 1, 2, 3, 4 and 5 days of incubation at 35-37 degrees C. Drug combinations enhanced slightly the killing of drugs alone. CIP+CLA was the most effective against MAC strains whereas CIP+RIF appeared as the best combination against rapidly growing species except M. phlei which was the most resistant strain.
Ximenes
E
E
Laboratoire de Bactériologie, Faculté de Pharmacie, Montpellier, France.
Zuccarelli
M
M
Dusart
G
G
Simeon De Buochberg
M
M
D002939:Ciprofloxacin / Q000494:pharmacology*; D017291:Clarithromycin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D009168:Mycobacterium phlei / Q000187:drug effects*; D009170:Nontuberculous Mycobacteria / Q000187:drug effects*; D012293:Rifampin / Q000494:pharmacology*
D002939:Ciprofloxacin; D017291:Clarithromycin; D012293:Rifampin
Ciprofloxacine, clarithromycine, rifampicine: activité bactéricide in vitro de doubles et triple associations sur des souches de mycobactéries atypiques.